© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, CytoMed Therapeutics Limited (GDTC) shows an Average True Range (ATR) of 0.1 and an Enterprise Value of 16.23M. Its average trading volume over the past 3 months is 74.42K, indicating liquidity. These fundamental metrics provide insight into GDTC's underlying financial health and market activity.
| ATR | 0.1 |
| Enterprise Value | 16.23M |
| Avg Vol (3 Months) | 74.42K |
| Avg Vol (10 Days) | 11.84K |
CytoMed Therapeutics Limited (GDTC) technical indicators as of September 12, 2026: the SMA 20 is 7.92%, SMA 50 at -7.11%, and SMA 200 at -40.77%. The RSI 14 value is 51.38, suggesting its current momentum. These technical analysis signals help assess GDTC's price trends and potential future movements.
| SMA 20 | 7.92% |
| SMA 50 | -7.11% |
| SMA 200 | -40.77% |
| RSI 14 | 51.38 |
CytoMed Therapeutics Limited (GDTC) stock performance overview as of September 12, 2026: The 52-week high is N/A (currently -70.65% below), and the 52-week low is N/A (currently 48.31% above). Over the past year, GDTC's performance is N/A, compared to the S&P 500's 0.26% change.
| 52-Week High | N/A |
| 52-Week High Chg | -70.65% |
| 52-Week Low | N/A |
| 52-Week Low Chg | +48.31% |
| S&P 500 52-Week Chg | 0.26% |
According to current financial data, GDTC stock's P/E (TTM) ratio is -2.42, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.25. Key valuation ratios for GDTC, including P/S (18.00), P/B (1.76), and P/FCF (-1.83), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
| Valuation | GDTC | Sector Median | Industry Avg | S&P 500 |
|---|---|---|---|---|
| P/E (TTM) | -2.42 | -1.25 | -194.38 | 32.59 |
| P/S (TTM) | 18 | 3.74 | 467.58 | 5.98 |
| P/B (TTM) | 1.76 | 1.28 | 15.86 | 5.59 |
| P/FCF (TTM) | -1.83 | -3.79 | -698.52 | 28.73 |